RCTs examining the effect of dihydropyridine CCB vs. placebo in overtly albuminuric patients with CKD and Type 2 DM [categorical outcomes]. Supplementary Table 51. RCTs examining the effect of aldosterone antagonist ACEI vs. placebo ACEI in patients with CKD and Type 2 DM [continuous outcomes]. Supplementary Table 52. RCTs examining the effect of endothelin antagonist vs. endothelin antagonist in patients with CKD with Type 2 DM [categorical outcomes]. Supplementary Table 53. RCTs examining the effect of endothelin antagonist vs. endothelin antagonist in patients with CKD with Type 2 DM [continuous outcomes]. Supplementary material is linked to the online version of the paper at http://www.kdigo.org/clinical_practice_guidelines/bp.php Chapter 5: Blood pressure management in kidney transplant recipients (CKD T) INTRODUCTION This chapter addresses the management of BP in adults with non dialysis-dependent CKD who have received a kidney transplant (CKD T). There is insufficient evidence to make recommendations specific to children with a kidney transplant. 5.1: We suggest that adult kidney transplant recipients whose office BP is consistently 4130 mm Hg systolic or 480 mm Hg diastolic be treated to maintain a BP that is consistently r130 mm Hg systolic and r80 mm Hg diastolic, irrespective of the level of urine albumin excretion. (2D) RATIONALE In adult kidney transplant recipients we consider two primary outcomes from the standpoint of BP: graft function and CVD. 